Broadwood的代理文件聚焦STAAR的控制权变更支付，声称高管将获得超过5500万美元的加速股权奖励，其中包括首席执行官Stephen ...

LumiThear's Valeda is an FDA-authorized treatment for dry age-related macular degeneration to improve vision. (LumiThera ...

Investing.com - Stifel将STAAR Surgical (NASDAQ: STAA )的评级从买入下调至持有，同时将目标价从20.00美元上调至28.00美元，此举是在Alcon宣布收购该公司后做出的。过去一周，STAAR股价已上涨超过50%， InvestingPro 数据显示该股目前处于超买区域。

Investing.com - STAAR Surgical Company (NASDAQ:STAA)即将被Alcon Inc.

近日，来自英国的顶级刹车品牌ALCON通过其中国独家总代理GUSTO（格时图）宣布，搭载国产高性能碳陶制动盘的ALCON碳陶刹车套件正式在中国市场发售。这一消息无疑为高性能车爱好者带来了新的选择，也为整车性能提升提供了更多可能性。

Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When ...

Broadwood Partners said today that it intends to vote against the proposed acquisition of Staar Surgical (Nasdaq:STAA) by Alcon (NYSE:ALC).

The acquisition includes the noninvasive Valeda PBM device for the treatment of early and intermediate dry age-related ...

Alcon has announced its launch of the first fully personalized LASIK treatment, wavelight plus, in the US and Canada. 1 The ...

STAAR Surgical (STAA) stock in focus as its biggest shareholder Broadwood Partners intends to vote against Alcon's $1.5B ...

I reiterate a 'Strong Buy' rating for Alcon with a one-year price target of $115 per share, driven by new product pipelines and FDA clearances. Alcon's Unity VCS/CS systems received FDA clearance, set ...